Literature DB >> 8082495

Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease.

J S Hyams1, J E Fitzgerald, N Wyzga, W R Treem, C J Justinich, D L Kreutzer.   

Abstract

The cytokines IL-1 beta and IL-6 appear to be important in the pathogenesis of inflammatory bowel disease (IBD). Recently, a naturally occurring interleukin-1 receptor antagonist, designated IL-1ra, which inhibits IL-1 beta activity in vitro and in vivo has been described. The purpose of the present study was to assess the circulating levels and relative relationships of IL-1ra, IL-1 beta, and IL-6 in children with IBD of varying severity. Serum/plasma samples were obtained from 32 children with ulcerative colitis, 45 with Crohn's disease, and 24 control patients. Cytokine assays were performed by enzyme-linked immunoassay. IL-1ra levels were significantly elevated in children with ulcerative colitis or Crohn's disease of moderate/severe activity compared to patients with inactive/mild IBD or control subjects (P < 0.001). IL-1 beta was only detectable in the circulation of two subjects with severe colitis (one ulcerative colitis, one Crohn's disease), and both had extremely elevated IL-1ra levels. IL-1ra levels were significantly related to IL-6 levels for patients with IBD (P < 0.00001). Our results suggest that circulating IL-1ra appears in increasing concentrations in children with mounting degrees of disease severity as determined by clinical scoring methods as well as by the level of IL-6. Future work will need to address the clinical and prognostic value of measuring circulating IL-1ra in individuals with inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082495     DOI: 10.1007/bf02088122

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Enhanced mucosal cytokine production in inflammatory bowel disease.

Authors:  W E Pullman; S Elsbury; M Kobayashi; A J Hapel; W F Doe
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

Review 2.  The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome.

Authors:  C A Dinarello
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

3.  Transforming growth factor-beta inhibition of interleukin-1 activity involves down-regulation of interleukin-1 receptors on chondrocytes.

Authors:  A K Harvey; P S Hrubey; S Chandrasekhar
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

4.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

5.  Examining the role of inflammatory cytokines in chronic inflammatory bowel disease.

Authors:  S N Lichtman; R B Sartor
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-04       Impact factor: 2.839

6.  Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease.

Authors:  J S Hyams; J E Fitzgerald; W R Treem; N Wyzga; D L Kreutzer
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

7.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

Authors:  S H Murch; V A Lamkin; M O Savage; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

8.  Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist.

Authors:  S M Wahl; G L Costa; M Corcoran; L M Wahl; A E Berger
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

9.  Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist.

Authors:  E Vannier; L C Miller; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease.

Authors:  J Brynskov; N Tvede; C B Andersen; M Vilien
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

View more
  6 in total

1.  Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders.

Authors:  Hirotada Akiho; Eikichi Ihara; Yasuaki Motomura; Kazuhiko Nakamura
Journal:  World J Gastrointest Pathophysiol       Date:  2011-10-15

2.  Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis.

Authors:  U T Hacker; M Gomolka; E Keller; A Eigler; C Folwaczny; H Fricke; E Albert; K Loeschke; S Endres
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

3.  Stress maladjustment in the pathoetiology of ulcerative colitis.

Authors:  Tsukasa Kuroki; Akihide Ohta; Yosuke Aoki; Seiji Kawasaki; Nozomi Sugimoto; Hibiki Ootani; Seiji Tsunada; Ryuichi Iwakiri; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

4.  Cytokines in inflammatory bowel disease.

Authors:  P L Beck; J L Wallace
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

5.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06

6.  Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis.

Authors:  Andrzej Wędrychowicz; Przemysław Tomasik; Andrzej Zając; Krzysztof Fyderek
Journal:  Arch Med Sci       Date:  2017-06-30       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.